Prolong Pharmaceuticals is Drug Discovery in United States that focus on debilitating comorbidities business. They cover business area such as developer, biopharmaceutical product, several disease, their debilitate comorbiditie, oxygen, tissue, blood sample, patient, sickle cell disease, (SCD, anemia, hypoxia, ischemia, healthcare practitioner, life, significant mortality, hematology and oncology product.
-
Debilitating Comorbidities
-
300 Corporate Court
Suite B
South Plainfield, NJ 07080
United States
Private
developerbiopharmaceutical productseveral diseasetheir debilitate comorbiditieoxygentissueblood samplepatientsickle cell disease(SCDanemiahypoxiaischemiahealthcare practitionerlifesignificant mortalityhematology and oncology product
* We use standard office opening hours in near Prolong Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Prolong Pharmaceuticals is Drug Discovery business from United States that founded in - ( years old in ), Prolong Pharmaceuticals business is focusing on Debilitating Comorbidities.
Prolong Pharmaceuticals headquarter office and corporate office address is located in 300 Corporate Court Suite B South Plainfield, NJ 07080 United States.
Prolong Pharmaceuticals was founded in United States.
In , Prolong Pharmaceuticals is currently focus on debilitating comorbidities sector.
Above is snippet of Google Trends for "debilitating comorbidities" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Prolong Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
